T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-09-09 12:48 (151 d 11:43 ago) – Posting: # 23282
Views: 1,123

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
15 visitors (0 registered, 15 guests [including 8 identified bots]).
Forum time: 23:32 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5